Sable Bio: AI-Driven Drug Safety Platform Secures £1.5 Million Funding
Established by a team of AI-driven drug discovery experts formerly at BenevolentAI, Sable aims to provide scientists with richer specialist data, initially concentrating on toxicology. Sable offers an AI-enhanced platform that seamlessly integrates multimodal data to produce actionable insights. The London-based company, founded in 2023 and headquartered in London, raised an oversubscribed £1.5 million pre-seed funding round, led by Episode 1 Ventures with participation from Seedcamp.
LONDON, 6 February 2024.
Sable Bio, an innovative B2B software startup changing how biotech and pharma companies evaluate drug target safety for effective decision-making, today announced the successful closure of an oversubscribed £1.5 million pre-seed funding round, led by Episode 1 Ventures supported by Seedcamp, and ex-Deepmind, now Finster AI CEO Siddhant Jayakumar. With unforeseen toxicity as a major driver of failure in drug discovery campaigns, Sable’s approach offers substantial cost and time savings in drug development, delivering safer drugs to patients in need more rapidly.
Sable facilitates broad access to specialist biomedical data, empowering scientists across different fields to make well-informed decisions about the safety of specific drug targets. The company is currently seeking to establish partnerships with biotech, pharma, and healthtech companies, as well as academic collaborations. The funding will enable building out a stellar team of scientists and engineers, enabling the refinement and enhancement of their core technological infrastructure, providing a solid and expansive foundation for their data capabilities.
About Sable Bio:
Sable Bio is developing a unique AI-enhanced platform designed to offer pharmaceutical companies predictive safety insights, mitigating the risk of clinical trial failures. Their innovative approach involves extracting proprietary signals from structured and unstructured data sources, leveraging large language models, causal inference techniques, and extensive domain knowledge.
About Episode 1 Ventures: Episode 1 is a leading early-stage fund investing £500k – £2m in seed and pre-seed B2B software companies across the UK. We are a team of founders, technologists, and operators who have been backing and building businesses for 20+ yrs.
About Seedcamp: Seedcamp is Europe’s seed fund, identifying and investing from Angel rounds to Seed in world-class founders attacking large, global markets and solving real problems using technology. The Seedcamp Nation includes over 490 startups building breakout businesses that change the way people live, interact, and buy, and includes publicly listed UiPath, Wise, and unicorns Revolut, Synthesia, Sorare, Pleo, wefox, and Grover, along with fast-growing businesses such as Peppy, Sylvera, Appwrite, Ramp, and Buynomics. Seedcamp fast-tracks a founder’s vision and creates value through immediate access to smart capital, a lifelong community of support, and a global network built upon more than 15 years’ experience backing exceptional talent.
They've invested in Sable Bio
Get to know these Healthtech investors
Click here for a full list of 6,481+ startup investors in the UK